Skip to main content

Advertisement

SpringerLink
Log in

Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients

  • Urologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

We investigated whether smoking cessation could have preventative effects against tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC).

Methods

Our study population comprised 634 patients with initially diagnosed NMIBC at Keio University Hospital, Saiseikai Central Hospital, and Saitama Medical University Hospital between 1995 and 2012. We analyzed the relationships between tumor recurrence in NMIBC and patient clinicopathological parameters, including smoking status.

Results

Overall, 181 patients (28.5 %) were classified as current smokers, 154 (24.3 %) as former smokers, and 299 (47.2 %) as non-smokers. Kaplan–Meier curve analysis revealed that the tumor recurrence rate was significantly lower in the non-smoker group than in the current- and former-smoker groups (p < 0.001 and p < 0.001, respectively). In the 154 former smokers, Kaplan–Meier curve analysis revealed that smoking intensity and duration was not associated with tumor recurrence rate; however, patients with a smoking cessation period of 15 years or more had a significantly lower tumor recurrence rate than their counterparts (p < 0.001). A multivariate analysis identified a smoking cessation period of <15 years (hazard ratio [HR] 2.20; p = 0.003) and T1 tumors (HR 1.99; p = 0.013) as independent risk factors for tumor recurrence in the former-smokers subgroup.

Conclusions

A positive smoking history was identified as one of the independent risk factors for bladder tumor recurrence after transurethral resection of the bladder tumor. Furthermore, refraining from smoking for 15 years or more reduced the risk of tumor recurrence in former smokers with NMIBC regardless of the intensity or duration of smoking. Therefore, smoking cessation may reduce the risk of tumor recurrence in patients with NMIBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–42.

    Article  PubMed  Google Scholar 

  2. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2014;65(4):742–54.

    Article  CAS  PubMed  Google Scholar 

  4. Grotenhuis AJ, Ebben CW, Aben KK, et al. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol. 2015;33(2):65.e69–17.

  5. Allard P, Fradet Y, Tetu B, Bernard P. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res. 1995;1(10):1195–202.

    CAS  PubMed  Google Scholar 

  6. Chen CH, Shun CT, Huang KH, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int. 2007;100(2):281–86; discussion 286.

  7. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol. 1999;17(10):3182–87.

    CAS  PubMed  Google Scholar 

  8. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer. 1999;86(11):2337–45.

    Article  CAS  PubMed  Google Scholar 

  9. Gangawar R, Ahirwar D, Mandhani A, Mittal RD. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med Oncol. 2010;27(2):159–66.

    Article  CAS  PubMed  Google Scholar 

  10. Gee JR, Jarrard DF, Bruskewitz RC, et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guerin. BJU Int. 2009;103(6):736–39.

    Article  CAS  PubMed  Google Scholar 

  11. Hwang EC, Kim YJ, Hwang IS, et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol. 2011;18(11):769–76.

    Article  PubMed  Google Scholar 

  12. Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol. 2011;60(4):713–20.

    Article  PubMed  Google Scholar 

  13. Rink M, Furberg H, Zabor EC, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol. 2013;63(4):724–32.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rink M, Xylinas E, Babjuk M, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2120–27.

    Article  PubMed  Google Scholar 

  15. Rink M, Xylinas E, Babjuk M, et al. Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol. 2012;62(6):1204–06.

    Article  PubMed  Google Scholar 

  16. Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int. 2012;109(7):1026–30.

    Article  PubMed  Google Scholar 

  17. Serretta V, Altieri V, Morgia G, Di Lallo A, Carrieri G, Allegro R. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. Urology. 2013;81(2):277–81.

    Article  PubMed  Google Scholar 

  18. Sfakianos JP, Shariat SF, Favaretto RL, Rioja J, Herr HW. Impact of smoking on outcomes after intravesical bacillus Calmette-Guerin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int. 2011;108(4):526–30.

    Article  CAS  PubMed  Google Scholar 

  19. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–53.

    Article  PubMed  Google Scholar 

  20. Al-Mamgani A, van Rooij PH, Woutersen DP, et al. Radiotherapy for T1-2N0 glottic cancer: a multivariate analysis of predictive factors for the long-term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients. Clin Otolaryngol. 2013;38(4):306–12.

    Article  CAS  PubMed  Google Scholar 

  21. Benninger MS, Gillen J, Thieme P, Jacobson B, Dragovich J. Factors associated with recurrence and voice quality following radiation therapy for T1 and T2 glottic carcinomas. Laryngoscope. 1994;104(3 Pt 1):294–98.

    CAS  PubMed  Google Scholar 

  22. Zhou W, Heist RS, Liu G, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer. 2006;53(3):375–80.

    Article  PubMed  Google Scholar 

  23. Sardari Nia P, Weyler J, Colpaert C, Vermeulen P, Van Marck E, Van Schil P. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer. 2005;47(3):351–59.

    Article  PubMed  Google Scholar 

  24. Videtic GM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol. 2003;21(8):1544–49.

    Article  PubMed  Google Scholar 

  25. Chernyavsky AI, Shchepotin IB, Grando SA. Mechanisms of growth-promoting and tumor-protecting effects of epithelial nicotinic acetylcholine receptors. Int Immunopharmacol. 2015;29(1):36–44.

    Article  CAS  PubMed  Google Scholar 

  26. Momi N, Ponnusamy MP, Kaur S, et al. Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through alpha7nAChR-mediated MUC4 upregulation. Oncogene. 2013;32(11):1384–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Schaal C, Chellappan SP. Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res. 2014;12(1):14–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Improgo MR, Tapper AR, Gardner PD. Nicotinic acetylcholine receptor-mediated mechanisms in lung cancer. Biochem Pharmacol. 2011;82(8):1015–21.

    Article  CAS  PubMed  Google Scholar 

  29. Yuge K, Kikuchi E, Hagiwara M, et al. Nicotine induces tumor growth and chemoresistance through activation of the PI3K/Akt/mTOR pathway in bladder cancer. Mol Cancer Ther. 2015;14(9):2112–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Koichiro Ogihara, Eiji Kikuchi, Kazuyuki Yuge, Yujiro Ito, Nobuyuki Tanaka, Kazuhiro Matsumoto, Akira Miyajima, Hirotaka Asakura, and Mototsugu Oya certify that this study has no financial or other relationships that might lead to a conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Keio University School of Medicine, Tokyo, Japan

    Koichiro Ogihara MD, Eiji Kikuchi MD, PhD, Kazuyuki Yuge MD, Nobuyuki Tanaka MD, PhD, Kazuhiro Matsumoto MD, Akira Miyajima MD, PhD & Mototsugu Oya MD, PhD

  2. Department of Urology, Saiseikai Central Hospital, Tokyo, Japan

    Yujiro Ito MD

  3. Department of Urology, Saitama Medical University Hospital, Saitama, Japan

    Hirotaka Asakura MD, PhD

Authors
  1. Koichiro Ogihara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eiji Kikuchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuyuki Yuge MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yujiro Ito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuyuki Tanaka MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Matsumoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akira Miyajima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirotaka Asakura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mototsugu Oya MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eiji Kikuchi MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogihara, K., Kikuchi, E., Yuge, K. et al. Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients. Ann Surg Oncol 23, 1752–1759 (2016). https://doi.org/10.1245/s10434-015-5016-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-5016-z

Keywords

Search

Navigation